These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 11301814)

  • 1. Lyme vaccine: issues and controversies.
    Rahn DW
    Infect Dis Clin North Am; 2001 Mar; 15(1):171-87. PubMed ID: 11301814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prevention of Lyme disease with vaccine.
    Poland GA; Jacobson RM
    Vaccine; 2001 Mar; 19(17-19):2303-8. PubMed ID: 11257352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvanted Lyme disease vaccine: a review of its use in the management of Lyme disease.
    Onrust SV; Goa KL
    Drugs; 2000 Feb; 59(2):281-99. PubMed ID: 10730551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccines against Lyme disease: What happened and what lessons can we learn?
    Poland GA
    Clin Infect Dis; 2011 Feb; 52 Suppl 3():s253-8. PubMed ID: 21217172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An open-label, nonrandomized, single-center, prospective extension, clinical trial of booster dose schedules to assess the safety profile and immunogenicity of recombinant outer-surface protein A (OspA) Lyme disease vaccine.
    Schoen RT; Deshefy-Longhi T; Van-Hoecke C; Buscarino C; Fikrig E
    Clin Ther; 2003 Jan; 25(1):210-24. PubMed ID: 12637121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Lyme disease vaccine--a public health perspective.
    Shen AK; Mead PS; Beard CB
    Clin Infect Dis; 2011 Feb; 52 Suppl 3():s247-52. PubMed ID: 21217171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A systematic review and meta-analysis for the adverse effects, immunogenicity and efficacy of Lyme disease vaccines: Guiding novel vaccine development.
    Badawi A; Shering M; Rahman S; Lindsay LR
    Can J Public Health; 2017 Apr; 108(1):e62-e70. PubMed ID: 28425901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity of a recombinant Borrelia burgdorferi outer surface protein A vaccine against lyme disease in healthy children and adolescents: a randomized controlled trial.
    Sikand VK; Halsey N; Krause PJ; Sood SK; Geller R; Van Hoecke C; Buscarino C; Parenti D;
    Pediatrics; 2001 Jul; 108(1):123-8. PubMed ID: 11433064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness analysis of the Lyme disease vaccine.
    Hsia EC; Chung JB; Schwartz JS; Albert DA
    Arthritis Rheum; 2002 Jun; 46(6):1651-60. PubMed ID: 12115198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccination of horses with Lyme vaccines for dogs induces short-lasting antibody responses.
    Guarino C; Asbie S; Rohde J; Glaser A; Wagner B
    Vaccine; 2017 Jul; 35(33):4140-4147. PubMed ID: 28668566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Lyme vaccine: a cautionary tale.
    Nigrovic LE; Thompson KM
    Epidemiol Infect; 2007 Jan; 135(1):1-8. PubMed ID: 16893489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lyme disease vaccine attitudes and intentions among parents of children aged 5-18 years in the United States.
    Gidengil C; Scherer AM; Parker AM; Gedlinske A; Fleck-Derderian S; Hinckley AF; Hook SA; Lindley MC; Marx GE
    Vaccine; 2024 Mar; 42(8):1899-1905. PubMed ID: 38418339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correcting a public health fiasco: The need for a new vaccine against Lyme disease.
    Plotkin SA
    Clin Infect Dis; 2011 Feb; 52 Suppl 3():s271-5. PubMed ID: 21217175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. American Academy of Pediatrics. Committee on Infecious Diseases. Prevention of Lyme disease.
    Pediatrics; 2000 Jan; 105(1 Pt 1):142-7. PubMed ID: 10617720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The novel Lyme borreliosis vaccine VLA15 shows broad protection against Borrelia species expressing six different OspA serotypes.
    Comstedt P; Schüler W; Meinke A; Lundberg U
    PLoS One; 2017; 12(9):e0184357. PubMed ID: 28863166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lyme disease.
    Evans J
    Curr Opin Rheumatol; 1995 Jul; 7(4):322-8. PubMed ID: 7547110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lyme disease.
    Evans J
    Curr Opin Rheumatol; 2000 Jul; 12(4):311-7. PubMed ID: 10910185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lyme vaccine demonized by advocacy groups.
    McSweegan E
    Nature; 2006 Mar; 440(7082):278. PubMed ID: 16541048
    [No Abstract]   [Full Text] [Related]  

  • 19. Lyme vaccine: studies have raised genuine concerns.
    Brenner C
    Nature; 2006 Mar; 440(7082):278. PubMed ID: 16541047
    [No Abstract]   [Full Text] [Related]  

  • 20. Safety and immunogenicity profile of a recombinant outer-surface protein A Lyme disease vaccine: clinical trial of a 3-dose schedule at 0, 1, and 2 months.
    Schoen RT; Sikand VK; Caldwell MC; Van Hoecke C; Gillet M; Buscarino C; Parenti DL
    Clin Ther; 2000 Mar; 22(3):315-25. PubMed ID: 10963286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.